{"filing":{"accession_number":"0001636282-26-000056","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"syre-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/syre-20260527.htm"},"events":[{"id":2255,"run_id":1961,"accession_number":"0001636282-26-000056","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Peter Harwin resigned from the Board effective May 27, 2026. The resignation was not due to disagreement with the company.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-05-29","items":[{"id":2880,"accession_number":"0001636282-26-000056","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Peter Harwin's resignation from the Board effective May 27, 2026 is the principal disclosed action in this Item 5.02. While the section also mentions stockholder approval of an amended ESPP, the departure of a director is a material governance event that would affect investor assessment of the company's board composition. The explicit statement that the resignation was not due to disagreement mitigates concerns but does not diminish materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:39:27.885401+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":2256,"run_id":1961,"accession_number":"0001636282-26-000056","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Shareholders voted at the May 27, 2026 Annual Meeting on four proposals: election of three Class I directors (McKenna, Turtle, Stelzer), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of the amended ESPP. Final vote tallies were disclosed for each proposal.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-05-29","items":[{"id":2881,"accession_number":"0001636282-26-000056","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the May 27, 2026 Annual Meeting of Stockholders, covering four proposals: election of three Class I directors (McKenna, Turtle, Stelzer), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of the AR ESPP. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 disclosures and is material to investors assessing corporate governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:39:27.885401+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2880,"accession_number":"0001636282-26-000056","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Peter Harwin's resignation from the Board effective May 27, 2026 is the principal disclosed action in this Item 5.02. While the section also mentions stockholder approval of an amended ESPP, the departure of a director is a material governance event that would affect investor assessment of the company's board composition. The explicit statement that the resignation was not due to disagreement mitigates concerns but does not diminish materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:39:27.885401+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-05-29"},{"id":2881,"accession_number":"0001636282-26-000056","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the May 27, 2026 Annual Meeting of Stockholders, covering four proposals: election of three Class I directors (McKenna, Turtle, Stelzer), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of the AR ESPP. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 disclosures and is material to investors assessing corporate governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:39:27.885401+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-05-29"}]}